Advanced Search

Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia Stocks List

Symbol Grade Name % Change
CRBU B Caribou Biosciences, Inc. 7.47
MBRX D Moleculin Biotech, Inc. 4.03
View As Page of Charts
Related Industries: Biotechnology
Related Stock Lists: Medicine Refractory Acute Myeloid Leukemia Acute Myeloid Leukemia Anthracycline Antineoplastic Drugs Biopharmaceutical Biotechnology Blastoma Breakthrough Therapy Cancer Cancer Immunotherapy CD19 Cell Biology Cell Therapy Chemotherapy Chimeric Antigen Receptor T Cell Clinical Medicine Glioblastoma Hematologic Malignancies Leukemia

Related ETFs - A few ETFs which own one or more of the above listed Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia stocks.

Symbol Grade Name Weight
XDNA C Kelly CRISPR & Gene Editing Technology ETF 5.23
CNCR C Loncar Cancer Immunotherapy ETF 2.88
CBLS C Changebridge Capital Long/Short Equity ETF 2.86
CBSE B Changebridge Capital Sustainable Equity ETF 2.14
GNOM C Global X Genomics & Biotechnology ETF 0.85
View all Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia ETFs...
Compare ETFs
Compare CNCR to GNOM Compare XDNA to CNCR Compare XDNA to GNOM

Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia Stocks Recent News

Date Stock Title
May 12 CRBU Caribou extends gains as SVB Leerink raises target after early data for CAR-T asset
May 12 CRBU Caribou's Lymphoma Candidate Shows 100% Response Rate In Early-Stage Study
May 12 CRBU Caribou Biosciences rises 27% on early-stage CAR-T therapy data for non-Hodgkin lymphoma
May 12 CRBU Caribou Biosciences Announces Positive Initial Data for CB-010 Anti-CD19 Allogeneic CAR-T Cell Therapy
May 12 MBRX Moleculin Biotech GAAP EPS of -$0.24 misses by $0.01
May 12 MBRX Moleculin Reports First Quarter 2022 Financial Results and Provides Programs Update
May 12 CRBU Here's What Analysts Are Forecasting For Caribou Biosciences, Inc. (NASDAQ:CRBU) After Its First-Quarter Results
May 11 CRBU Caribou Biosciences Announces Appointment of David Johnson to its Board of Directors
May 10 MBRX Moleculin Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
Related Industries: Biotechnology
Related Stock Lists: Medicine Refractory Acute Myeloid Leukemia Acute Myeloid Leukemia Anthracycline Antineoplastic Drugs Biopharmaceutical Biotechnology Blastoma Breakthrough Therapy Cancer Cancer Immunotherapy CD19 Cell Biology Cell Therapy Chemotherapy Chimeric Antigen Receptor T Cell Clinical Medicine Glioblastoma Hematologic Malignancies Leukemia

Browse All Tags